114 related articles for article (PubMed ID: 16579055)
1. [Effect of the class III antiarrhythmic drug nibentan in vagotonic atrial fibrillation].
Popova EP; Lyskovtsev VV; Kaverina NV
Eksp Klin Farmakol; 2006; 69(1):24-7. PubMed ID: 16579055
[TBL] [Abstract][Full Text] [Related]
2. [Comparative study of the electrophysiological properties of class iii medicinals (cardiocyclide, nibentan, sotalol) and evaluation of their efficacy in atrial fibrillation produced by auricular and vagal stimulation].
Kaverina NV; Lyskovtsev VV; Popova EP
Eksp Klin Farmakol; 2007; 70(1):11-6. PubMed ID: 17402585
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new class III antiarrhythmic drug nibentan in a canine model of vagally mediated atrial fibrillation.
Fedorov VV; Sharifov OF; Beloshapko GG; Yushmanova AV; Rosenshtraukh LV
J Cardiovasc Pharmacol; 2000 Jul; 36(1):77-89. PubMed ID: 10892664
[TBL] [Abstract][Full Text] [Related]
4. [A comparative study of the effects of antiarrhythmic class III drugs cardiocyclide and sotalol on the atrioventricular fibrillation caused by vagus nerve excitation in narcotized dogs].
Popova EP
Eksp Klin Farmakol; 2005; 68(4):28-32. PubMed ID: 16193653
[TBL] [Abstract][Full Text] [Related]
5. [Comparative study of electrophysiological mechanisms of anti-arrhythmia III class agents, cardiocyclide, nibentan, and sotalol during experimental myocardial infarction and sympathetic stimulation].
Kaverina NV; Lyskovtsev VV; Popova EP
Eksp Klin Farmakol; 2003; 66(1):27-33. PubMed ID: 12683077
[TBL] [Abstract][Full Text] [Related]
6. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.
Wang J; Feng J; Nattel S
Circulation; 1994 Oct; 90(4):2032-40. PubMed ID: 7923691
[TBL] [Abstract][Full Text] [Related]
7. [The first original Russian class-III antiarrhythmic nibentan].
Glushkov RG; Golitsyn SP; Dorodnikova EV; Maĭkov EB; Mashkovskiĭ MD; Merkulova IN; Rozenshtraukh LV; Ruda MIa; Skachilova SIa; Chazov EI; Iuzhakov SD
Vestn Ross Akad Med Nauk; 1998; (11):38-41. PubMed ID: 9889704
[TBL] [Abstract][Full Text] [Related]
8. [Nibentan -- a drug for pharmacological cardioversion of persistent atrial fibrillation].
Shubik IuV; Medvedev MM; Rivin AE
Kardiologiia; 2005; 45(3):19-23. PubMed ID: 15821703
[TBL] [Abstract][Full Text] [Related]
9. [Afobasol efficacy in a model of vagotonic atrial fibrillation].
Stoliaruk VN; Vititnova MB; Tsorin IB; Kryzhanovskiĭ SA
Vestn Ross Akad Med Nauk; 2010; (4):49-52. PubMed ID: 20540357
[TBL] [Abstract][Full Text] [Related]
10. Different effects of class Ic and III antiarrhythmic drugs on vagotonic atrial fibrillation in the canine heart.
Hayashi H; Fujiki A; Tani M; Usui M; Inoue H
J Cardiovasc Pharmacol; 1998 Jan; 31(1):101-7. PubMed ID: 9456284
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias.
Gautier P; Serre M; Cosnier-Pucheu S; Djandjighian L; Roccon A; Herbert JM; Nisato D
J Cardiovasc Pharmacol; 2005 Feb; 45(2):125-35. PubMed ID: 15654261
[TBL] [Abstract][Full Text] [Related]
12. [Nibentan in arresting acute atrial fibrillation: risk or benefit?].
Chapurnykh AV; Solov'ev OV; Zavalin AV; Pavlov EG; Efremov DN
Ter Arkh; 2008; 80(1):41-5. PubMed ID: 18326226
[TBL] [Abstract][Full Text] [Related]
13. Effects of a novel class III antiarrhythmic agent, NIP-142, on canine atrial fibrillation and flutter.
Nagasawa H; Fujiki A; Fujikura N; Matsuda T; Yamashita T; Inoue H
Circ J; 2002 Feb; 66(2):185-91. PubMed ID: 11999646
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study of the anti-arrhythmic activity of cardiocyclide and nibentan in hypersympathotonia and acute myocardial ischemia].
Vititnova MB; Kryzhanovskiĭ SA; Kaverina NV
Eksp Klin Farmakol; 2002; 65(2):24-6. PubMed ID: 12109286
[TBL] [Abstract][Full Text] [Related]
15. Heart rate variability is a useful parameter for evaluation of anticholinergic effect associated with inducibility of atrial fibrillation.
Sugiura H; Chinushi M; Komura S; Hirono T; Aizawa Y
Pacing Clin Electrophysiol; 2005 Nov; 28(11):1208-14. PubMed ID: 16359288
[TBL] [Abstract][Full Text] [Related]
16. Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity.
Iwasa A; Okumura K; Tabuchi T; Tsuchiya T; Tsunoda R; Matsunaga T; Tayama S; Yasue H
Eur J Pharmacol; 1998 Aug; 356(1):31-40. PubMed ID: 9761421
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiologic effects of nibentan (HE-11) on canine cardiac tissue.
Anyukhovsky EP; Sosunov EA; Rosen MR
J Pharmacol Exp Ther; 1997 Mar; 280(3):1137-46. PubMed ID: 9067296
[TBL] [Abstract][Full Text] [Related]
18. Role of the atrial rate as a factor modulating ventricular response during atrial fibrillation.
Climent AM; Guillem MS; Husser D; Castells F; Millet J; Bollmann A
Pacing Clin Electrophysiol; 2010 Dec; 33(12):1510-7. PubMed ID: 20636310
[TBL] [Abstract][Full Text] [Related]
19. [The cholinolytic activity of the new anti-arrhythmia preparation Nibentan].
Fedorov VV; Vinogradova TM; Bogdanov KIu; Rozenshtraukh LV
Ross Fiziol Zh Im I M Sechenova; 1999 Mar; 85(3):383-94. PubMed ID: 10494589
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological restoration and maintenance of sinus rhythm by antiarrhythmic agents].
Sugi K
J Cardiol; 1999 Mar; 33 Suppl 1():59-64. PubMed ID: 10342138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
